LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Начало・Списък с акции・BioNTech SE ADR

BioNTech SE ADR

Затворен

СекторЗдравеопазване

89.38 1.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

87.99

Максимум

91.01

Ключови измерители
By Trading Economics
Приходи	-239M -541M
Продажби	-779M 120M
EPS	-1.95
Марж на печалбата	-450.381
Служители	7,807
EBITDA	-481M -549M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+50.9% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.9B 23B
Предишно отваряне	88.27
Предишно затваряне	89.38

Настроения в новините

By Acuity

17%

83%

30 / 344 Класиране в Healthcare

BioNTech SE ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.05.2026 г., 18:12 ч. UTC

Печалби

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5.05.2026 г., 13:54 ч. UTC

Печалби

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

10.03.2026 г., 12:50 ч. UTC

Печалби

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10.03.2026 г., 11:18 ч. UTC

Печалби

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

4.08.2025 г., 14:14 ч. UTC

Печалби

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped. -- Barrons.com

4.08.2025 г., 11:59 ч. UTC

Печалби

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

12.06.2025 г., 14:20 ч. UTC

Придобивния, сливания и поглъщания

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12.06.2025 г., 13:34 ч. UTC

Горещи акции

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

10.06.2025 г., 12:18 ч. UTC

Печалби

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

BioNTech SE ADR Прогноза

Ценова цел

By TipRanks

50.9% нагоре

12-месечна прогноза

Среден 133.47 USD 50.9%

Висок 167 USD

Нисък 94 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за BioNTech SE ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

Купи

Задържане

Продай

Според 18 анализатори, дали борсови рейтинги на BioNTech SE ADR през последните 3 месеца.

Настроение

By Acuity

30 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac